Assistant Professor, Medicine-Massachusetts General Hospital, Harvard Medical School
Oncology
Dr. Edwin Choy, MD
|
|
Give Review
Edwin Choy is an expert in the field of Oncology. He attended NYU School of Medicine. He over the years received 1 awards: "Regional Top Doctor". Edwin Choy has written publications. He has 44 publications published with PubMed. The lastest publication is: 'Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.' Edwin Choy, MD accepts Medicare payments and is registered with Medicare.gov.
Publications
- NVP-TAE684 reverses multidrug resistance (MDR) in human osteoSarcoma by inhibiting P-glycoprotein (PGP1) function.
- p53 overexpression increases chemosensitivity in multidrug-resistant osteoSarcoma cell lines.
- Targeting protein kinases to reverse multidrug resistance in Sarcoma.
- Eribulin versus dacarbazine in previously treated patients with advanced lipoSarcoma or leiomyoSarcoma: a randomised, open-label, multicentre, phase 3 trial.
- Denosumab-treated Giant Cell Tumor of Bone Exhibits Morphologic Overlap With Malignant Giant Cell Tumor of Bone.
- Tibial stress reaction presenting as bilateral shin pain in a man taking denosumab for giant cell tumor of the bone.
- CD44 is a direct target of miR-199a-3p and contributes to aggressive progression in osteoSarcoma.
- Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in Chordoma.
- NSC23925 prevents the emergence of multidrug resistance in ovarian Cancer in vitro and in vivo.
- MicroRNA-155 expression is independently predictive of outcome in Chordoma.
- Prognostic significance of treatment-induced pathologic necrosis in extremity and truncal soft tissue Sarcoma after neoadjuvant chemoradiotherapy.
- Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer.
- Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic Sarcoma.
- Inhibition of Vascular Endothelial Growth Factor A and Hypoxia-Inducible Factor 1α Maximizes the Effects of Radiation in Sarcoma Mouse Models Through Destruction of Tu...
- Case records of the Massachusetts General Hospital. Case 33-2014. A 60-year-old man with bone pain.
- Prevention of multidrug resistance (MDR) in osteoSarcoma by NSC23925.
- Sarcoma after 5 years of progression-free survival: Lessons from the French Sarcoma Group.
- Programmed Cell Death Ligand 1 Expression in OsteoSarcoma.
- Biosimilar safety considerations in clinical practice.
- Prognostic significance of miRNA-1 (miR-1) expression in patients with Chordoma.
- Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imati...
- MRI surveillance following treatment of extremity soft tissue Sarcoma.
- Update in treatment and targets in Ewing Sarcoma.
- Role of epigenetic modulation for the treatment of Sarcoma.
- Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of lipoSarcoma cells.
- Targeting hedgehog-GLI-2 pathway in osteoSarcoma.
- Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal Sarcomas: a 10-year single institution retrospective study.
- Desmoid tumor: Analysis of prognostic factors and outcomes in a surgical series.
- Systematic Kinome shRNA Screening Identifies CDK11 (PITSLRE) Kinase Expression is Critical for Osteosarcoma Cell Growth and Proliferation.
- High-throughput genotyping in osteoSarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes.
- Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial.
- Tivantinib (ARQ 197), a selective inhibitor of mesenchymal-epithelial transition factor, in patients with microphthalmia transcription factor-associated Tumors: Result...
- Establishment and characterization of a novel Chordoma cell line: CH22.
- Synthesis and Evaluation of (2-(4-Methoxyphenyl)-4-quinolinyl)(2-piperidinyl)methanol (NSC23925) Isomers To Reverse Multidrug Resistance in Cancer.
- Role of sentinel lymph node biopsy in the staging of synovial, epithelioid, and clear cell Sarcomas.
- Targeting programmed cell death ligand 1 in osteoSarcoma: an auto-commentary on therapeutic potential.
- MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian Cancer.
- Phase II study of olaparib in patients with refractory Ewing Sarcoma following failure of standard chemotherapy.
- A-770041 reverses paclitaxel and doxorubicin resistance in osteoSarcoma cells.
- Genotyping Cancer-Associated Genes in Chordoma Identifies Mutations in Oncogenes and Areas of Chromosomal Loss Involving CDKN2A, PTEN, and SMARCB1.
- Synergistic Effects of Targeted PI3K Signaling Inhibition and Chemotherapy in LipoSarcoma.
- Tissue Microarray Immunohistochemical Detection of Brachyury Is Not a Prognostic Indicator in Chordoma.
- SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced Sarcoma.
Schools
New York University
Ma Gnrl Hospital
Dana Farber Cancer Center
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Regional Top Doctor
Education
-
Massachusetts General Hospital -
NYU School of Medicine
Hospital
-
Massachusetts General Hospital
Drug Facts
| NPI NUMBER | 1760466106 | |
| NPPES Provider LastName | CHOY | |
| NPPES Provider FirstName | EDWIN | |
| NPPES Provider ZIPCode | 021501812 | |
| NPPES Provider State | MA | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 166.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1760466106 |
| Last Name Of The Provider | CHOY |
| First Name Of The Provider | EDWIN |
| View All |
Similar Doctors
|
|
Dr. Elizabeth A. Guancial, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Wei Wang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Sheheryar K. Kabraji, MB CHB
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jonathan Carlson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ronald W. Takvorian, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jane C. Weeks, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Panagiotis Konstantinopoulos, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Richard A. Robinson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christina I. Herold, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kenneth A. Bauer, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Brian M. Wolpin, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Joseph P. Eder, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sridhar Ramaswamy, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Adam Lerner, MD
This Doctor is OpenDoctor Recommended.
|